However, as SRPIN340 inhibits SRPK1 and to a lesser extent SRPK2, as well other splicing kinases (Fukuhara et al., 2006), these data are limited in informing which SRPK1/2 member is relevant for melanoma progression. Here, SRPK2 is linked to melanoma.